Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total value of $40,378.20. Following the completion of the transaction, the insider now directly owns 164,475 shares in the company, valued at $2,845,417.50. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Soleil Boughton also recently made the following trade(s):
- On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.29, for a total transaction of $47,377.15.
- On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80.
- On Thursday, May 30th, Soleil Boughton sold 129,667 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.55, for a total transaction of $2,664,656.85.
- On Tuesday, May 28th, Soleil Boughton sold 2,502 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.33, for a total value of $43,359.66.
- On Monday, May 20th, Soleil Boughton sold 4,915 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.01, for a total value of $98,349.15.
- On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.33, for a total value of $30,861.99.
Hims & Hers Health Stock Performance
Shares of HIMS traded up $0.11 during midday trading on Friday, hitting $15.96. 8,244,545 shares of the stock traded hands, compared to its average volume of 7,900,966. The business’s 50 day moving average price is $21.12 and its two-hundred day moving average price is $15.91. The firm has a market capitalization of $3.43 billion, a PE ratio of -1,596.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74.
Hedge Funds Weigh In On Hims & Hers Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Arizona State Retirement System increased its stake in Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after buying an additional 1,173 shares during the period. Belpointe Asset Management LLC increased its stake in shares of Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares during the period. Victory Capital Management Inc. raised its holdings in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after purchasing an additional 1,212 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Hims & Hers Health by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after purchasing an additional 1,561 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the period. 63.52% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the company. Jefferies Financial Group upped their price target on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Truist Financial raised their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, Citigroup lowered Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their target price for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $20.00.
Check Out Our Latest Research Report on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Recommended Stories
- Five stocks we like better than Hims & Hers Health
- What is Forex and How Does it Work?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Canadian Penny Stocks: Can They Make You Rich?
- MarketBeat Week in Review – 8/5 – 8/9
- What is an Earnings Surprise?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.